<DOC>
	<DOCNO>NCT01241903</DOCNO>
	<brief_summary>The central hypothesis work platelet - leukocyte interaction play critical role pathogenesis acute ischemic event . The primary objective study determine early , high-dose administration HMG-CoA reductase inhibitor rosuvastatin set acute coronary syndrome percutaneous coronary intervention exert beneficial vascular effect reduce platelet - leukocyte interaction .</brief_summary>
	<brief_title>Early Use Rosuvastatin Acute Coronary Syndromes : Targeting Platelet-Leukocyte Interactions</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Subjects must 18 80 year old . 2 . Subjects must willing able give inform consent 3 . A woman childbearing potential currently sexually active must agree use medically accept method contraception receive protocolspecified medication 30 day enrollment . 4 . Subjects must symptoms acute coronary syndrome define 2 3 : ( ) history cardiacischemiarelated symptom least 10 minute duration ≤ 8 hour prior randomize treatment assignment ( b ) concurrent biomarker evidence cardiac ischemia , define troponin I T great upper limit normal ( ULN ) creatine kinasemyocardial band ( CKMB ) great ULN . ( c ) concurrent electrocardiographic evidence cardiac ischemia , define new presumably new STsegment depression ( ≥1 mm ) transient ( &lt; 30 min ) STsegment elevation ( ≥ 1mm ) least two contiguous lead . 5 . Subjects must statin naive currently low dose statin ( Simvastatin 20mg , Pravastatin 40mg , Atorvastatin 10mg ) Age &lt; 18 year Age &gt; 80 year Use Crestor past 30 day GFR ( estimate ) &lt; 30 ml/min Hemodialysis History liver failure Unexplained liver function abnormality Current plan use cyclosporine gemfibrozil Sepsis Hypotension Dehydration Trauma Severe metabolic , endocrine electrolyte abnormality Recent ( within last 2 week ) plan ( next month ) major surgery HIV/AIDS current plan use HIV protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Platelet activation</keyword>
	<keyword>platelet leukocyte aggregate</keyword>
</DOC>